How to use infliximab?
|
|
- Gwendoline Barton
- 5 years ago
- Views:
Transcription
1 How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven
2 The how to use infliximab rules Before starting IFX: try optimizing chances for response! Once response: maintain the efficacy! Avoid immunogenicity! When to stop?
3 The how to use infliximab rules Before starting IFX: try optimizing chances for response! Once response: maintain the efficacy! Avoid immunogenicity! When to stop?
4 Optimizing induction of remission 3 Dose Induction vs. Single Dose? 3 dose induction Single dose % pats. Responding P= Weeks Infusions Hanauer S et al; Lancet 2002; 359:
5 Optimizing induction of remission: cotreatment? p< response (%) Luminal CD Fistulising CD imunosuppressives no immunosuppressives Parsi et al; Gastroenterol 2002; 123: Arnott et al; APT. 2003;17:1451-7
6 Optimizing induction of remission: cotreatment? Vermeire S et al, Am J Gastroenterol 2002; 97:
7 Optimizing induction of remission: smoking 100 p< response (%) Luminal CD Fistulising CD Smokers Non smokers Parsi et al; Gastroenterology 2002; 123: Arnott et al; APT. 2003;17:1451-7
8 Conclusion: Predictive factors for response to infliximab Clinical Genetic Other Confirmed Concom immunosuppression Increased CRP Colonic disease Non Smoking Short duration of disease Not confirmed young age LTA haplotype ASCA/pANCA early age at onset FcGR III a-158 Non stricturing FasL-843 TUCAN Cys10* No impact Severity of disease TNF previous therapies NOD2/CARD15 previous resections
9 The how to use infliximab rules Before starting IFX: try optimizing chances for response! Once response: maintain the efficacy! Avoid immunogenicity! When to stop?
10 70 60 Initial Treatment Phase Retreatment Phase Responders at 8 weeks (n=73) % Responding Infliximab (n=37) Placebo (n=36) Week Infusions Most patients will need retreatment! Rutgeerts P, et al. Gastroenterology. 1999; 117:76-69
11
12 ACCENT II
13 which strategy is the best? 1. IFX episodic in monotherapy? 2. IFX episodic + IS? 3. IFX every 8 weeks in monotherapy? 4. IFX every eight weeks + IS? 5. IFX as bridge for IS? Main goal: maintain efficacy and avoid loss of response = optimize not immunize
14 Mouse antibody The problem of immunogenicity Humanized antibody Mouse sequences Chimeric antibody Human sequences
15 Mouse antibody The problem of immunogenicity Humanized antibody Chimeric antibody Infliximab (Remicade ) Mouse sequences Human sequences CDP571 (Humicade ) CDP870 (PEGylated) Adalimumab (Humira )
16 Antibodies to infliximab (ATI) (formerly HACA) % of Patients Antibody (+) 100% 80% 60% 40% 20% 0% N=125 61% Number of infusions Baert F-Noman M et al NEJM 2003; 348;
17 Duration of Response by ATI Days until subsequent Infusion P<0.001 Negative µg/ml µg/ml > 20 µg/ml [Antibodies to Infliximab] Baert F-Noman M et al NEJM 2003; 348;
18 ATI and Immunosuppressant Tx P<0.01 % of patients antibody (+) 100% 80% 60% 40% 20% 0% 43.0% n= 56 Taking Immunossuppressant 75.0% n= 69 Not taking Immunosuppressants Baert F-Noman M et al NEJM 2003; 348;
19 Infliximab and Immunosuppressant Tx Taking Immunosuppressants Not Taking Immunosuppressants Median serum concentration µg/ml Non-fistula Fistula Non-fistula Fistula Baert F-Noman M et al NEJM 2003; 348;
20 % of patients ATI and MTX or AZA? Does it matter? p = NS neg 73 pos inconcl No IS MTX AZA treatment group Noman M et al DDW 2004
21 ATI Formation and steroid pretreatment Farrell et al, Gastro 2003
22 which strategy is the best? 1. IFX episodic in monotherapy? NO 2. IFX episodic + IS? YES 3. IFX every 8 weeks in monotherapy? 4. IFX every eight weeks + IS? 5. IFX as bridge for IS?
23 which strategy is the best? 1. IFX episodic in monotherapy? NO 2. IFX episodic + IS? YES 3. IFX every 8 weeks in monotherapy? YES 4. IFX every eight weeks + IS? YES 5. IFX as bridge for IS? YES
24 Clinical Response Through Week 54 All Patients Including Episodic Retreatment 80 Proportion of Patients (%) Weeks from the Initial Infusion Single dose (n = 188) 5 mg/kg q 8 wks (n = 192) 10 mg/kg q 8 wks (n = 193) Hanauer S et al; Lancet 2002; 359:
25 Antibodies to Infliximab % of patients Overall No IS IS 0 Episodic Treatment 5 mg/kg q 8wks 10 mg/kg q 8wks Hanauer S et al. Clin Gastroenterol Hepatol. 2004;2: ACCENT I
26 ACCENT I Infliximab: Endoscopic Healing Single dose Patients Demonstrating Endoscopic Healing (%) P=0.007 P= % 46% P= % 7% 0/17 10/32 1/14 5/11 8/15 Week 10 Week 54 Combined dose group (5 mg/kg & 10 mg/kg infliximab maintenance) 5 mg/kg infliximab maintenance 10 mg/kg infliximab maintenance Rutgeerts P et al. Gastroenterology. 2002;122(suppl):A-618
27
28
29 Fistulizing CD: time to loss of response at week 54 Patients without loss of response (%) Week 14 responders P<0.001 Induction Maintenance Weeks Episodic (n=99) Infliximab maintenance 5 mg/kg (n=96) Sands B et al; NEJM 2004;350:
30
31 Loss of response over time Step up to 10 mg/kg Shorten interval to less than 8 weeks Consider more humanized antibodies
32 IFX as a bridge for immunosuppressives Infliximab (Week 0, 2, 6) + AZA/MP Steroid dependence > 6 months Stratum 1 ( AZA failure ) AZA 2-3 mg/kg/d (or MP)> 6 mo continued Stratum 2 ( AZA naive ) AZA 2-2,5 mg/kg/d Steroid tapering standardized scheme increase of dose in case of relapse withdrawal if resistance to pred>40 mg/d for 2 wks Placebo (Week 0, 2, 6) + AZA/MP Week 24 End-point Week 52 Follow-up Lemann et al Gut Suppl 2003; 52: A44
33 Remission (CDAI<150) & off steroids 100% 80% 60% 40% 20% 0% P=0.009 P=0.03 P=0.02 P= % 64% 63% 50% 41% 34% 32% 26% Naive Failure Naive Failure Week 12 Week 24 AZA failure (n=56) AZA naive (n=59) Placebo week 0, 2, 6 + AZA/MP Infliximab 5 mg/kg week 0, 2, 6 + AZA/MP Lemann et al Gut 2003; 52: A44
34 Conclusion: optimizing IFX: induction of remission Consider 3-induction regimen (certainly for fistulizing CD) Give/optimize concomitant immunosuppressive therapy Advise patients to stop smoking
35 Conclusion: optimizing IFX: maintenance Eight-weekly IFX preferred over episodic strategy (less immunogenicity, better mucosal healing) Concomitant immunosuppression when episodic strategy is used Eight-weekly IFX for fistulizing CD (long term) Consider pretreatment with hydrocortisone How long to continue immunosuppressives when IFX is given eight-weekly? Consider step up dose to 10 mg/kg if loss of response over time More humanized antibodies for future
36 How long should we continue IFX? No controlled data beyond one year Experience from large centers up to 10 years Try to stop when treatment goal is reached: discontinuation of GCS with maintained remission complete external healing of fistulas continue with immunosuppressives Restart IFX when relapse Placebo-controlled IFX discontinuation study needed
Immunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationThe advent of infliximab (Remicade; Centocor, Optimizing Anti-TNF Treatment in Inflammatory Bowel Disease
GASTROENTEROLOGY 2004;126:1593 1610 Optimizing Anti-TNF Treatment in Inflammatory Bowel Disease PAUL RUTGEERTS, GERT VAN ASSCHE, and SÉVERINE VERMEIRE Department of Medicine, Division of Gastroenterology,
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationLevels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn s Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:421 427 Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn s Disease MATTHIAS JÜRGENS,* JESTINAH M. MAHACHIE
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationBiologic agents, such as monoclonal antibodies
PREDICTING, MEASURING, AND MAINTAINING RESPONSE TO TNF-α ANTAGONISTS IN INFLAMMATORY BOWEL DISEASE Stephen B. Hanauer, MD * ABSTRACT Tumor necrosis factor (TNF) antagonists have substantially improved
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn s Disease
The new england journal of medicine original article Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn s Disease Filip Baert, M.D., Maja Noman, M.D., Severine Vermeire, M.D.,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationLessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis
Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Aránzazu Jáuregui Amézaga, Elena Ricart, Julián Panés Department of Gastroenterology, Hospital Clínic de Barcelona,
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationAre Biologicals Safe Enough?
Are Biologicals Safe Enough? Dr Anne Duggan Director of Gastroenterology, John Hunter Hospital, Hunter New England Area Health Service (HNEAHS) Conjoint A/Professor, University of Newcastle, Australia
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationReview article: infliximab therapy for inflammatory bowel disease seven years on
Alimentary Pharmacology & Therapeutics Review article: infliximab therapy for inflammatory bowel disease seven years on P. RUTGEERTS, G. VAN ASSCHE & S. VERMEIRE Department of Medicine, Division of Gastroenterology,
More informationIntravenous Hydrocortisone Premedication Reduces Antibodies to Infliximab in Crohn s Disease: A Randomized Controlled Trial
GASTROENTEROLOGY 2003;124:917 924 Intravenous Hydrocortisone Premedication Reduces Antibodies to Infliximab in Crohn s Disease: A Randomized Controlled Trial RICHARD J. FARRELL, MAZEN ALSAHLI, YOON TAE
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationThe Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study
ORIGINAL ARTICLE The Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study Norimitsu Uza, Hiroshi Nakase, Satoru Ueno, Satoko Inoue, Sakae Mikami, Hiroyuki Tamaki,
More informationClinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Gut and Liver, Published online September 9, 2016 ORiginal Article Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease So Yoon
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationMedical Management of Small bowel Crohn s Disease: An evidence-based approach
Medical Management of Small bowel Crohn s Disease: An evidence-based approach E. Jan Irvine, M.D., F.R.C.P.(C)., M.Sc. Professor of Medicine, University of Toronto, Head, Division of Gastroenterology,
More informationAssociation of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn s Disease
CLINICL GSTROENTEROLOGY ND HEPTOLOGY 26;4:1248 1254 ssociation of Trough Serum Infliximab to Clinical Outcome fter Scheduled Maintenance Treatment for Crohn s Disease ELN. MSER, RENT VILLEL, MRK S. SILVERERG,
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationInfliximab Therapy in Pediatric Patients 7 Years of Age and Younger
ORIGINAL ARTICLE: GASTROENTEROLOGY Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger Judith R. Kelsen, Andrew B. Grossman, Helen Pauly-Hubbard, Kernika Gupta, Robert N. Baldassano, and
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationSubmitted by xxxxxxxxxxxxxxxxx, xxxxxxxxx RCP and co-ordinated by xxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxx, Royal Liverpool University Hospital.
Royal College of Physicians statement on the appraisal of use of tumour necrosis factor alpha (TNF-α) inhibitors (adalimumab, certolizumab pegol and infliximab) and natalizumab for Crohn's disease Submitted
More informationPreventing post-operative recurrence
Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting Talk Outline Risk factors for
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationSpecial Authorization Drug Products with
Effective August 1, 2008 Summary Special Authorization Drug Products with Changes to Criteria Special Authorization Drug Products with Changes to Criteria Alberta Blue Cross has been advised by Alberta
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More information